<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32815157</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-1128</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Medicinal research reviews</Title><ISOAbbreviation>Med Res Rev</ISOAbbreviation></Journal><ArticleTitle>In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches.</ArticleTitle><Pagination><StartPage>2804</StartPage><EndPage>2822</EndPage><MedlinePgn>2804-2822</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/med.21725</ELocationID><Abstract><AbstractText>Recent progress in understanding the pathological changes in the nervous system and in certain other body systems (e.g., immune system) that lead to the development and progression of amyotrophic lateral sclerosis (ALS) revealed a number of molecular and cellular processes that can potentially be used as therapeutic targets. Many of these processes are compromised not only in ALS but also in other diseases and a repertoire of drugs able to restore, at least partially, their functionality has been developed. In this review, we briefly describe current approaches to the repurposing of such "old" drugs for treatment of patients with ALS.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kukharsky</LastName><ForeName>Michail S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0001-5080-2544</Identifier><AffiliationInfo><Affiliation>Faculty of Medical Biology, Pirogov Russian National Research Medical University, Moscow, Russian Federation.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Sciences, Moscow Region, Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skvortsova</LastName><ForeName>Veronika I</ForeName><Initials>VI</Initials><AffiliationInfo><Affiliation>Faculty of Medical Biology, Pirogov Russian National Research Medical University, Moscow, Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachurin</LastName><ForeName>Sergey O</ForeName><Initials>SO</Initials><Identifier Source="ORCID">0000-0003-3637-818X</Identifier><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Sciences, Moscow Region, Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchman</LastName><ForeName>Vladimir L</ForeName><Initials>VL</Initials><Identifier Source="ORCID">0000-0002-7631-8352</Identifier><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Russian Academy of Sciences, Moscow Region, Russian Federation.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biosciences, Cardiff University, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Res Rev</MedlineTA><NlmUniqueID>8103150</NlmUniqueID><ISSNLinking>0198-6325</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="Y">Pharmaceutical Preparations</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">disease mechanisms</Keyword><Keyword MajorTopicYN="N">drugs</Keyword><Keyword MajorTopicYN="N">therapeutic strategies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32815157</ArticleId><ArticleId IdType="doi">10.1002/med.21725</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hardiman O , Al-Chalabi A , Chio A , et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.</Citation></Reference><Reference><Citation>Rowland LP , Shneider NA . Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688-1700.</Citation></Reference><Reference><Citation>Masrori P , Van Damme P . Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14393</Citation></Reference><Reference><Citation>Haverkamp LJ , Appel V , Appel SH . Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118(Pt 3):707-719.</Citation></Reference><Reference><Citation>Mehta P , Kaye W , Raymond J , et al. Prevalence of amyotrophic lateral sclerosis-United States, 2014. MMWR Morb Mortal Wkly Rep. 2018;67(7):216-218.</Citation></Reference><Reference><Citation>Neumann M , Sampathu DM , Kwong LK , et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130-133.</Citation></Reference><Reference><Citation>Brown RH Jr. , Al-Chalabi A . Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(16):1602.</Citation></Reference><Reference><Citation>Mathis S , Goizet C , Soulages A , Vallat JM , Masson GL . Genetics of amyotrophic lateral sclerosis: a review. J Neurol Sci. 2019;399:217-226.</Citation></Reference><Reference><Citation>Alsultan AA , Waller R , Heath PR , Kirby J . The genetics of amyotrophic lateral sclerosis: current insights. Degener Neurol Neuromuscul Dis. 2016;6:49-64.</Citation></Reference><Reference><Citation>Nowicka N , Juranek J , Juranek JK , Wojtkiewicz J . Risk factors and emerging therapies in amyotrophic lateral sclerosis. Int J Mol Sci. 2019;20:11.</Citation></Reference><Reference><Citation>Ferraiuolo L , Kirby J , Grierson AJ , Sendtner M , Shaw PJ . Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):616-630.</Citation></Reference><Reference><Citation>Mejzini R , Flynn LL , Pitout IL , Fletcher S , Wilton SD , Akkari PA . ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310.</Citation></Reference><Reference><Citation>Miller RG , Bouchard JP , Duquette P , et al. Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47(4 suppl 2):S86-S90.</Citation></Reference><Reference><Citation>Miller RG , Mitchell JD , Moore DH . Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:CD001447.</Citation></Reference><Reference><Citation>Chio A , Mazzini L , Mora G . Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020;167:107986.</Citation></Reference><Reference><Citation>Jaiswal MK . Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733-748.</Citation></Reference><Reference><Citation>Writing Group,&#xa0;Edaravone (MCI-186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512.</Citation></Reference><Reference><Citation>Taylor JP , Brown RH Jr. , Cleveland DW . Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197-206.</Citation></Reference><Reference><Citation>Phukan J , Elamin M , Bede P , et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2012;83(1):102-108.</Citation></Reference><Reference><Citation>Lomen-Hoerth C , Anderson T , Miller B . The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59(7):1077-1079.</Citation></Reference><Reference><Citation>Boxer AL , Mackenzie IR , Boeve BF , et al. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry. 2011;82(2):196-203.</Citation></Reference><Reference><Citation>Turner MR , Goldacre R , Talbot K , Goldacre MJ . Psychiatric disorders prior to amyotrophic lateral sclerosis. Ann Neurol. 2016;80(6):935-938.</Citation></Reference><Reference><Citation>O'Brien M , Burke T , Heverin M , et al. Clustering of neuropsychiatric disease in first-degree and second-degree relatives of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2017;74(12):1425-1430.</Citation></Reference><Reference><Citation>Byrne S , Heverin M , Elamin M , et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann Neurol. 2013;74(5):699-708.</Citation></Reference><Reference><Citation>McLaughlin RL , Schijven D , van Rheenen W , et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat Commun. 2017;8:14774.</Citation></Reference><Reference><Citation>DeJesus-Hernandez M , Mackenzie IR , Boeve BF , et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256.</Citation></Reference><Reference><Citation>Renton AE , Majounie E , Waite A , et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268.</Citation></Reference><Reference><Citation>Renton AE , Chio A , Traynor BJ . State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17-23.</Citation></Reference><Reference><Citation>Cammack AJ , Atassi N , Hyman T , et al. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology. 2019;93(17):e1605-e1617.</Citation></Reference><Reference><Citation>Jiang J , Ravits J . Pathogenic mechanisms and therapy development for C9orf72 amyotrophic lateral sclerosis/frontotemporal dementia. Neurotherapeutics. 2019;16(4):1115-1132.</Citation></Reference><Reference><Citation>Silverman HE , Goldman JS , Huey ED . Links between the C9orf72 repeat expansion and psychiatric symptoms. Curr Neurol Neurosci Rep. 2019;19(12):93.</Citation></Reference><Reference><Citation>Oguro-Ando A , Zuko A , Kleijer KTE , Burbach JPH . A current view on contactin-4, -5, and -6: implications in neurodevelopmental disorders. Mol Cell Neurosci. 2017;81:72-83.</Citation></Reference><Reference><Citation>Farokhnia M , Sabzabadi M , Pourmahmoud H , et al. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacology (Berl). 2014;231(3):533-542.</Citation></Reference><Reference><Citation>Patten SA , Aggad D , Martinez J , et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight. 2017;2:22.</Citation></Reference><Reference><Citation>Bancila M , Copin JC , Daali Y , Schatlo B , Gasche Y , Bijlenga P . Two structurally different T-type Ca2+ channel inhibitors, mibefradil and pimozide, protect CA1 neurons from delayed death after global ischemia in rats. Fundam Clin Pharmacol. 2011;25(4):469-478.</Citation></Reference><Reference><Citation>Enyeart JJ , Biagi BA , Mlinar B . Preferential block of T-type calcium channels by neuroleptics in neural crest-derived rat and human C cell lines. Mol Pharmacol. 1992;42(2):364-372.</Citation></Reference><Reference><Citation>Enyeart JJ , Dirksen RT , Sharma VK , Williford DJ , Sheu SS . Antipsychotic pimozide is a potent Ca2+ channel blocker in heart. Mol Pharmacol. 1990;37(5):752-757.</Citation></Reference><Reference><Citation>Pozzi S , Thammisetty SS , Julien JP . Chronic administration of pimozide fails to attenuate motor and pathological deficits in two mouse models of amyotrophic lateral sclerosis. Neurotherapeutics. 2018;15:715-727.</Citation></Reference><Reference><Citation>Naganska E , Matyja E , Taraszewska A , Rafalowska J . Protective effect of valproic acid on cultured motor neurons under glutamate excitotoxic conditions. Ultrastructural study. Folia Neuropathol. 2015;53(4):309-316.</Citation></Reference><Reference><Citation>Jiang HZ , Wang SY , Yin X , et al. Downregulation of Homer1b/c in SOD1 G93A models of ALS: a novel mechanism of neuroprotective effect of lithium and valproic acid. Int J Mol Sci. 2016;17:12.</Citation></Reference><Reference><Citation>de Bartolomeis A , Tomasetti C , Cicale M , Yuan PX , Manji HK . Chronic treatment with lithium or valproate modulates the expression of Homer1b/c and its related genes Shank and inositol 1,4,5-trisphosphate receptor. Eur Neuropsychopharmacol. 2012;22(7):527-535.</Citation></Reference><Reference><Citation>Wang SY , Ren M , Jiang HZ , et al. Notch pathway is activated in cell culture and mouse models of mutant SOD1-related familial amyotrophic lateral sclerosis, with suppression of its activation as an additional mechanism of neuroprotection for lithium and valproate. Neuroscience. 2015;301:276-288.</Citation></Reference><Reference><Citation>Gupta A , Schulze TG , Nagarajan V , et al. Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. Pharmacogenomics J. 2012;12(4):328-341.</Citation></Reference><Reference><Citation>Wang X , Ma M , Teng J , et al. Valproate attenuates 25-kDa C-terminal fragment of TDP-43-induced neuronal toxicity via suppressing endoplasmic reticulum stress and activating autophagy. Int J Biol Sci. 2015;11(7):752-761.</Citation></Reference><Reference><Citation>Leng Y , Liang MH , Ren M , Marinova Z , Leeds P , Chuang DM . Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci. 2008;28(10):2576-2588.</Citation></Reference><Reference><Citation>Tomasetti C , Dell'Aversano C , Iasevoli F , Marmo F , de Bartolomeis A . The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):184-197.</Citation></Reference><Reference><Citation>Fornai F , Longone P , Cafaro L , et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2008;105(6):2052-2057.</Citation></Reference><Reference><Citation>Fornai F , Siciliano G , Manca ML , Murri L , Paparelli A , Ruggieri S . Lithium in ALS: from the bench to the bedside. Amyotroph Lateral Scler. 2008;9(2):123-124.</Citation></Reference><Reference><Citation>Ferrucci M , Spalloni A , Bartalucci A , et al. A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium. Neurobiol Dis. 2010;37(2):370-383.</Citation></Reference><Reference><Citation>Verstraete E , Veldink JH , Huisman MH , et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry. 2012;83(5):557-564.</Citation></Reference><Reference><Citation>Chi&#xf2; A , Borghero G , Calvo A , et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology. 2010;75(7):619-625.</Citation></Reference><Reference><Citation>Miller RG , Moore DH , Forshew DA , et al. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology. 2011;77(10):973-979.</Citation></Reference><Reference><Citation>Aggarwal SP , Zinman L , Simpson E , et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(5):481-488.</Citation></Reference><Reference><Citation>Group,&#xa0;UK-LS , Morrison KE , Dhariwal S , et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(4):339-345.</Citation></Reference><Reference><Citation>Gamez J , Salvado M , Martinez de la Ossa A , Badia M . Lithium for treatment of amyotrophic lateral sclerosis: much ado about nothing. Neurologia. 2016;31(8):550-561.</Citation></Reference><Reference><Citation>van Es MA , Veldink JH , Saris CG , et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41(10):1083-1087.</Citation></Reference><Reference><Citation>Diekstra FP , Van Deerlin VM , van Swieten JC , et al. C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis. Ann Neurol. 2014;76(1):120-133.</Citation></Reference><Reference><Citation>Placek K , Baer GM , Elman L , et al. UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2019;73:190-199.</Citation></Reference><Reference><Citation>van Eijk RPA , Jones AR , Sproviero W , et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89(18):1915-1922.</Citation></Reference><Reference><Citation>Feng HL , Leng Y , Ma CH , Zhang J , Ren M , Chuang DM . Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience. 2008;155(3):567-572.</Citation></Reference><Reference><Citation>Boll MC , Bayliss L , Vargas-Ca&#xf1;as S , et al. Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2014;340(1-2):103-108.</Citation></Reference><Reference><Citation>Peters OM , Ghasemi M , Brown RH Jr. Emerging mechanisms of molecular pathology in ALS. J Clin Invest. 2015;125(5):1767-1779.</Citation></Reference><Reference><Citation>McAlary L , Plotkin SS , Yerbury JJ , Cashman NR . Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:262.</Citation></Reference><Reference><Citation>Wang M , Kaufman RJ . Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature. 2016;529(7586):326-335.</Citation></Reference><Reference><Citation>Walter P , Ron D . The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334(6059):1081-1086.</Citation></Reference><Reference><Citation>Oakes SA , Papa FR . The role of endoplasmic reticulum stress in human pathology. Annu Rev Pathol. 2015;10:173-194.</Citation></Reference><Reference><Citation>Urra H , Dufey E , Lisbona F , Rojas-Rivera D , Hetz C . When ER stress reaches a dead end. Biochim Biophys Acta. 2013;1833(12):3507-3517.</Citation></Reference><Reference><Citation>Rozas P , Bargsted L , Martinez F , Hetz C , Medinas DB . The ER proteostasis network in ALS: determining the differential motoneuron vulnerability. Neurosci Lett. 2017;636:9-15.</Citation></Reference><Reference><Citation>Saxena S , Caroni P . Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron. 2011;71(1):35-48.</Citation></Reference><Reference><Citation>Atkin JD , Farg MA , Walker AK , McLean C , Tomas D , Horne MK . Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. Neurobiol Dis. 2008;30(3):400-407.</Citation></Reference><Reference><Citation>Hetz C , Thielen P , Matus S , et al. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 2009;23(19):2294-2306.</Citation></Reference><Reference><Citation>Ilieva EV , Ayala V , Jov&#xe9; M , et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain. 2007;130(Pt 12):3111-3123.</Citation></Reference><Reference><Citation>Farg MA , Soo KY , Walker AK , et al. Mutant FUS induces endoplasmic reticulum stress in amyotrophic lateral sclerosis and interacts with protein disulfide-isomerase. Neurobiol Aging. 2012;33(12):2855-2868.</Citation></Reference><Reference><Citation>Gonzalez-Perez P , Woehlbier U , Chian RJ , et al. Identification of rare protein disulfide isomerase gene variants in amyotrophic lateral sclerosis patients. Gene. 2015;566(2):158-165.</Citation></Reference><Reference><Citation>Yang Q , Guo ZB . Polymorphisms in protein disulfide isomerase are associated with sporadic amyotrophic lateral sclerosis in the Chinese Han population. Int J Neurosci. 2016;126(7):607-611.</Citation></Reference><Reference><Citation>Parakh S , Atkin JD . Protein folding alterations in amyotrophic lateral sclerosis. Brain Res. 2016;1648(Pt B):633-649.</Citation></Reference><Reference><Citation>Ruegsegger C , Saxena S . Proteostasis impairment in ALS. Brain Res. 2016;1648(Pt B):571-579.</Citation></Reference><Reference><Citation>Watkins TA , Wang B , Huntwork-Rodriguez S , et al. DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury. Proc Natl Acad Sci USA. 2013;110(10):4039-4044.</Citation></Reference><Reference><Citation>Welsbie DS , Yang Z , Ge Y , et al. Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. Proc Natl Acad Sci USA. 2013;110(10):4045-4050.</Citation></Reference><Reference><Citation>Pozniak CD , Sengupta Ghosh A , Gogineni A , et al. Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degeneration. J Exp Med. 2013;210(12):2553-2567.</Citation></Reference><Reference><Citation>Le Pichon CE , Meilandt WJ , Dominguez S , et al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci Transl Med. 2017;9:403.</Citation></Reference><Reference><Citation>Uppala JK , Gani AR , Ramaiah KVA . Chemical chaperone, TUDCA unlike PBA, mitigates protein aggregation efficiently and resists ER and non-ER stress induced HepG2 cell death. Sci Rep. 2017;7(1):3831.</Citation></Reference><Reference><Citation>Ozcan U , Yilmaz E , Ozcan L , et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137-1140.</Citation></Reference><Reference><Citation>Ackerman HD , Gerhard GS . Bile acids in neurodegenerative disorders. Front Aging Neurosci. 2016;8:263.</Citation></Reference><Reference><Citation>Thams S , Lowry ER , Larraufie MH , et al. A stem cell-based screening platform identifies compounds that desensitize motor neurons to endoplasmic reticulum stress. Mol Ther. 2019;27(1):87-101.</Citation></Reference><Reference><Citation>Elia AE , Lalli S , Monsurr&#xf2; MR , et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45-52.</Citation></Reference><Reference><Citation>Min JH , Hong YH , Sung JJ , Kim SM , Lee JB , Lee KW . Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. J Korean Med Sci. 2012;27(2):200-206.</Citation></Reference><Reference><Citation>Ludolph AC . The TUDCA trial-innovative trial designs for amyotrophic lateral sclerosis drugs? Eur J Neurol. 2016;23(1):11-12.</Citation></Reference><Reference><Citation>Kolb PS , Ayaub EA , Zhou W , Yum V , Dickhout JG , Ask K . The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis. Int J Biochem Cell Biol. 2015;61:45-52.</Citation></Reference><Reference><Citation>Cudkowicz ME , Andres PL , Macdonald SA , et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009;10(2):99-106.</Citation></Reference><Reference><Citation>Ryu H , Smith K , Camelo SI , et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;93(5):1087-1098.</Citation></Reference><Reference><Citation>Corman A , Jung B , H&#xe4;ggblad M , et al. A chemical screen identifies compounds limiting the toxicity of C9ORF72 dipeptide repeats. Cell Chem Biol. 2019;26(2):235-243.</Citation></Reference><Reference><Citation>Del Signore SJ , Amante DJ , Kim J , et al. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler. 2009;10(2):85-94.</Citation></Reference><Reference><Citation>Petri S , Kiaei M , Kipiani K , et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2006;22(1):40-49.</Citation></Reference><Reference><Citation>Kieran D , Kalmar B , Dick JR , Riddoch-Contreras J , Burnstock G , Greensmith L . Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nature Med. 2004;10(4):402-405.</Citation></Reference><Reference><Citation>Benatar M , Wuu J , Andersen PM , et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90(7):e565-e574.</Citation></Reference><Reference><Citation>Batulan Z , Shinder GA , Minotti S , et al. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. J Neurosci. 2003;23(13):5789-5798.</Citation></Reference><Reference><Citation>Manzerra P , Brown IR . Expression of heat shock genes (hsp70) in the rabbit spinal cord: localization of constitutive and hyperthermia-inducible mRNA species. J Neurosci Res. 1992;31(4):606-615.</Citation></Reference><Reference><Citation>Batulan Z , Nalbantoglu J , Durham HD . Nonsteroidal anti-inflammatory drugs differentially affect the heat shock response in cultured spinal cord cells. Cell Stress Chaperones. 2005;10(3):185-196.</Citation></Reference><Reference><Citation>Kuta R , Larochelle N , Fernandez M , et al. Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models. Cell Stress Chaperones. 2020;25(1):173-191.</Citation></Reference><Reference><Citation>van den Bos MAJ , Geevasinga N , Higashihara M , Menon P , Vucic S . Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques. Int J Mol Sci. 2019;20:11.</Citation></Reference><Reference><Citation>King AE , Woodhouse A , Kirkcaldie MT , Vickers JC . Excitotoxicity in ALS: overstimulation, or overreaction? Exp Neurol. 2016;275(Pt 1):162-171.</Citation></Reference><Reference><Citation>Deeks ED . Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. CNS Drugs. 2011;25(10):887-900.</Citation></Reference><Reference><Citation>Kovalchuk MO , Heuberger J , Sleutjes B , et al. Acute effects of riluzole and retigabine on axonal excitability in patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled, crossover trial. Clin Pharmacol Ther. 2018;104(6):1136-1145.</Citation></Reference><Reference><Citation>Wainger B. &#xa0;Ezogabine treatment shown to reduce motor neuron excitability in ALS patients; 2018. https://www.massgeneral.org/neurology/als/news/ezogabine-reduces-motor-neuron-excitability. Accessed 30 January 2020.</Citation></Reference><Reference><Citation>Wilson SM , Khanna R . Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide. Mol Neurobiol. 2015;51(2):599-609.</Citation></Reference><Reference><Citation>Ahn JY , Yan BC , Park JH , et al. Novel antiepileptic drug lacosamide exerts neuroprotective effects by decreasing glial activation in the hippocampus of a gerbil model of ischemic stroke. Exp Ther Med. 2015;10(6):2007-2014.</Citation></Reference><Reference><Citation>Kim GH , Byeon JH , Eun BL . Neuroprotective effect of lacosamide on hypoxic-ischemic brain injury in neonatal rats. J Clin Neurol. 2017;13(2):138-143.</Citation></Reference><Reference><Citation>Gencpinar P , Basaranlar G , Sati L , Duman O , Derin N . Effects of chronic topiramate, lacosamide, and levetiracetam pre-treatment on a status epilepticus model in rat pups. Neurophysiology. 2019;51(1):35-42.</Citation></Reference><Reference><Citation>Oskarsson B , Moore D , Mozaffar T , et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: a randomized, double-blind crossover trial. Muscle Nerve. 2018;58:42-48.</Citation></Reference><Reference><Citation>Weiss MD , Macklin EA , Simmons Z , et al. A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. Neurology. 2016;86(16):1474-1481.</Citation></Reference><Reference><Citation>Stys PK , Lesiuk H . Correlation between electrophysiological effects of mexiletine and ischemic protection in central nervous system white matter. Neuroscience. 1996;71(1):27-36.</Citation></Reference><Reference><Citation>Shibuya K , Misawa S , Kimura H , et al. A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: efficacy and safety of sodium channel blocker phase II trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):353-358.</Citation></Reference><Reference><Citation>Bensimon G , Lacomblez L , Meininger V , ALS/Riluzole Study Group . A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585-591.</Citation></Reference><Reference><Citation>Bensimon G , Lacomblez L , Delumeau JC , et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249(5):609-615.</Citation></Reference><Reference><Citation>Reddy BM , Weintraub HS , Schwartzbard AZ . Ranolazine: a new approach to treating an old problem. Tex Heart Inst J. 2010;37(6):641-647.</Citation></Reference><Reference><Citation>Schram G , Zhang L , Derakhchan K , Ehrlich JR , Belardinelli L , Nattel S . Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol. 2004;142(8):1300-1308.</Citation></Reference><Reference><Citation>Chaitman BR . Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006;113(20):2462-2472.</Citation></Reference><Reference><Citation>Peters CH , Sokolov S , Rajamani S , Ruben PC . Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons. Br J Pharmacol. 2013;169(3):704-716.</Citation></Reference><Reference><Citation>Park YY , Johnston D , Gray R . Slowly inactivating component of Na+ current in peri-somatic region of hippocampal CA1 pyramidal neurons. J Neurophysiol. 2013;109(5):1378-1390.</Citation></Reference><Reference><Citation>Gould HJ 3rd , Garrett C , Donahue RR , Paul D , Diamond I , Taylor BK . Ranolazine attenuates behavioral signs of neuropathic pain. Behav Pharmacol. 2009;20(8):755-758.</Citation></Reference><Reference><Citation>Gould HJ 3rd , Diamond I . Ranolazine: a potential treatment for refractory neuropathic pain. J Neurol Sci. 2016;369:310-311.</Citation></Reference><Reference><Citation>Kahlig KM , Hirakawa R , Liu L , George AL Jr. , Belardinelli L , Rajamani S . Ranolazine reduces neuronal excitability by interacting with inactivated states of brain sodium channels. Mol Pharmacol. 2014;85(1):162-174.</Citation></Reference><Reference><Citation>Kahlig KM , Lepist I , Leung K , Rajamani S , George AL . Ranolazine selectively blocks persistent current evoked by epilepsy-associated Nanu1.1 mutations. Br J Pharmacol. 2010;161(6):1414-1426.</Citation></Reference><Reference><Citation>Aldasoro M , Guerra-Ojeda S , Aguirre-Rueda D , et al. Effects of ranolazine on astrocytes and neurons in primary culture. PLOS One. 2016;11(3):e0150619.</Citation></Reference><Reference><Citation>Joo IS , Hwang DH , Seok JI , Shin SK , Kim SU . Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Clinical Neurol. 2007;3(4):181-186.</Citation></Reference><Reference><Citation>Wang R , Zhang D . Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci. 2005;22(9):2376-2380.</Citation></Reference><Reference><Citation>Levine TD , Bowser R , Hank N , Saperstein D . A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph Lateral Scler. 2010;11(6):514-519.</Citation></Reference><Reference><Citation>de Carvalho M , Pinto S , Costa J , Evangelista T , Ohana B , Pinto A . A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(5):456-460.</Citation></Reference><Reference><Citation>Bezzi P , Carmignoto G , Pasti L , et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature. 1998;391(6664):281-285.</Citation></Reference><Reference><Citation>Sanzgiri RP , Araque A , Haydon PG . Prostaglandin E(2) stimulates glutamate receptor-dependent astrocyte neuromodulation in cultured hippocampal cells. J Neurobiol. 1999;41(2):221-229.</Citation></Reference><Reference><Citation>Drachman DB , Frank K , Dykes-Hoberg M , et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2002;52(6):771-778.</Citation></Reference><Reference><Citation>Klivenyi P , Kiaei M , Gardian G , Calingasan NY , Beal MF . Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2004;88(3):576-582.</Citation></Reference><Reference><Citation>Kiaei M , Kipiani K , Petri S , et al. Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2005;93(2):403-411.</Citation></Reference><Reference><Citation>Cudkowicz ME , Shefner JM , Schoenfeld DA , et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60(1):22-31.</Citation></Reference><Reference><Citation>Zu T , Liu Y , Ba&#xf1;ez-Coronel M , et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci USA. 2013;110(51):E4968-E4977.</Citation></Reference><Reference><Citation>Mori K , Arzberger T , Gr&#xe4;sser FA , et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013;126(6):881-893.</Citation></Reference><Reference><Citation>Tabet R , Schaeffer L , Freyermuth F , et al. CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts. Nat Commun. 2018;9(1):152.</Citation></Reference><Reference><Citation>Rotermund C , Machetanz G , Fitzgerald JC . The therapeutic potential of metformin in neurodegenerative diseases. Front Endocrinol (Lausanne). 2018;9:400.</Citation></Reference><Reference><Citation>Westergard T , McAvoy K , Russell K , et al. Repeat-associated non-AUG translation in C9orf72-ALS/FTD is driven by neuronal excitation and stress. EMBO Mol Med. 2019;11:2.</Citation></Reference><Reference><Citation>Kaneb HM , Sharp PS , Rahmani-Kondori N , Wells DJ . Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLOS One. 2011;6(9):e24189.</Citation></Reference><Reference><Citation>Naujock M , Stanslowsky N , Bufler S , et al. 4-Aminopyridine induced activity rescues hypoexcitable motor neurons from amyotrophic lateral sclerosis patient-derived induced pluripotent stem cells. Stem Cells. 2016;34(6):1563-1575.</Citation></Reference><Reference><Citation>Mart&#xed;nez-Silva ML , Imhoff-Manuel RD , Sharma A , et al. Hypoexcitability precedes denervation in the large fast-contracting motor units in two unrelated mouse models of ALS. eLife. 2018;7:7.</Citation></Reference><Reference><Citation>Devlin AC , Burr K , Borooah S , et al. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat Commun. 2015;6:5999.</Citation></Reference><Reference><Citation>Peikert K , Naumann M , Gunther R , Wegner F , Hermann A . Off-label treatment of 4 amyotrophic lateral sclerosis patients with 4-aminopyridine. J Clin Pharmacol. 2019;59(10):1400-1404.</Citation></Reference><Reference><Citation>Aizawa H , Hideyama T , Yamashita T , et al. Deficient RNA-editing enzyme ADAR2 in an amyotrophic lateral sclerosis patient with a FUS(P525L) mutation. J Clin Neurosci. 2016;32:128-129.</Citation></Reference><Reference><Citation>Hideyama T , Yamashita T , Aizawa H , et al. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis. 2012;45(3):1121-1128.</Citation></Reference><Reference><Citation>Kawahara Y , Ito K , Sun H , Aizawa H , Kanazawa I , Kwak S . Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427(6977):801.</Citation></Reference><Reference><Citation>Takuma H , Kwak S , Yoshizawa T , Kanazawa I . Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol. 1999;46(6):806-815.</Citation></Reference><Reference><Citation>Moore S , Alsop E , Lorenzini I , et al. ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD. Acta Neuropathol. 2019;138(1):49-65.</Citation></Reference><Reference><Citation>Yamashita T , Kwak S . Cell death cascade and molecular therapy in ADAR2-deficient motor neurons of ALS. Neurosci Res. 2019;144:4-13.</Citation></Reference><Reference><Citation>Yamashita T , Kwak S . The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients. Brain Res. 2014;1584:28-38.</Citation></Reference><Reference><Citation>Aizawa H , Sawada J , Hideyama T , et al. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol. 2010;120(1):75-84.</Citation></Reference><Reference><Citation>Akamatsu M , Yamashita T , Hirose N , Teramoto S , Kwak S . The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep. 2016;6:28649.</Citation></Reference><Reference><Citation>Orrell RW , Lane RJ , Ross M . Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2007;1:CD002829.</Citation></Reference><Reference><Citation>Orrell RW , Lane RJ , Ross M . A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Amyotroph Lateral Scler. 2008;9(4):195-211.</Citation></Reference><Reference><Citation>Brooks BR , Jorgenson JA , Newhouse BJ , Shefner JM , Agnese W . Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy-a roundtable discussion. Am J Manag Care. 2018;24(9 suppl):S175-S186.</Citation></Reference><Reference><Citation>Takei K , Watanabe K , Yuki S , Akimoto M , Sakata T , Palumbo J . Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):5-10.</Citation></Reference><Reference><Citation>Veyrat-Durebex C , Corcia P , Mucha A , et al. Iron metabolism disturbance in a French cohort of ALS patients. BioMed Res Int. 2014;2014:485723.</Citation></Reference><Reference><Citation>Adachi Y , Sato N , Saito Y , et al. Usefulness of SWI for the detection of iron in the motor cortex in amyotrophic lateral sclerosis. J Neuroimaging. 2015;25(3):443-451.</Citation></Reference><Reference><Citation>Kwan JY , Jeong SY , Van Gelderen P , et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLOS One. 2012;7(4):e35241.</Citation></Reference><Reference><Citation>Ignjatovi&#x107; A , Stevi&#x107; Z , Lavrni&#x107; D , et al. Inappropriately chelated iron in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler. 2012;13(4):357-362.</Citation></Reference><Reference><Citation>Sheykhansari S , Kozielski K , Bill J , et al. Redox metals homeostasis in multiple sclerosis and amyotrophic lateral sclerosis: a review. Cell Death Dis. 2018;9(3):348.</Citation></Reference><Reference><Citation>Galey JB . Potential use of iron chelators against oxidative damage. Adv Pharmacol. 1997;38:167-203.</Citation></Reference><Reference><Citation>Jomova K , Valko M . Importance of iron chelation in free radical-induced oxidative stress and human disease. Curr Pharm Des. 2011;17(31):3460-3473.</Citation></Reference><Reference><Citation>Petillon C , Hergesheimer R , Puy H , et al. The relevancy of data regarding the metabolism of iron to our understanding of deregulated mechanisms in ALS; hypotheses and pitfalls. Front Neurosci. 2018;12:1031.</Citation></Reference><Reference><Citation>Zarbin M . Treatment of oxidative stress with chelation therapy. Arch Ophthalmol. 2012;130(12):1597-1598.</Citation></Reference><Reference><Citation>Moreau C , Danel V , Devedjian JC , et al. Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis? Antioxid Redox Signal. 2018;29(8):742-748.</Citation></Reference><Reference><Citation>Hilton JB , Mercer SW , Lim NK , et al. Cu(II)(atsm) improves the neurological phenotype and survival of SOD1(G93A) mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci Rep. 2017;7:42292.</Citation></Reference><Reference><Citation>McAllum EJ , Lim NK , Hickey JL , et al. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7-8):586-590.</Citation></Reference><Reference><Citation>Soon CP , Donnelly PS , Turner BJ , et al. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem. 2011;286(51):44035-44044.</Citation></Reference><Reference><Citation>Roberts BR , Lim NK , McAllum EJ , et al. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2014;34(23):8021-8031.</Citation></Reference><Reference><Citation>Vieira FG , Hatzipetros T , Thompson K , et al. CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits. IBRO Rep. 2017;2:47-53.</Citation></Reference><Reference><Citation>Ikawa M , Okazawa H , Arakawa K , et al. PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion. 2009;9(2):144-148.</Citation></Reference><Reference><Citation>Ikawa M , Okazawa H , Kudo T , Kuriyama M , Fujibayashi Y , Yoneda M . Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET. Nucl Med Biol. 2011;38(7):945-951.</Citation></Reference><Reference><Citation>Ikawa M , Okazawa H , Tsujikawa T , et al. Increased oxidative stress is related to disease severity in the ALS motor cortex: a PET study. Neurology. 2015;84(20):2033-2039.</Citation></Reference><Reference><Citation>Southon A , Szostak K , Acevedo KM , et al. Cu(II)(atsm) inhibits ferroptosis: implications for treatment of neurodegenerative disease. Br J Pharmacol. 2020;177(3):656-667.</Citation></Reference><Reference><Citation>Rowe D , Mathers S , Smith G , et al. Modification of ALS disease progression in a phase 1 trial of CuATSM. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(sup1):280-281.</Citation></Reference><Reference><Citation>Chen X , Burdett TC , Desjardins CA , et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci USA. 2013;110(1):300-305.</Citation></Reference><Reference><Citation>Chamorro A , Dirnagl U , Urra X , Planas AM . Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol. 2016;15(8):869-881.</Citation></Reference><Reference><Citation>Paganoni S , Schwarzschild MA . Urate as a marker of risk and progression of neurodegenerative disease. Neurotherapeutics. 2017;14(1):148-153.</Citation></Reference><Reference><Citation>Yu ZF , Bruce-Keller AJ , Goodman Y , Mattson MP . Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res. 1998;53(5):613-625.</Citation></Reference><Reference><Citation>O'Reilly &#xc9;J , Liu D , Johns DR , et al. Serum urate at trial entry and ALS progression in EMPOWER. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1-2):120-125.</Citation></Reference><Reference><Citation>Paganoni S , Nicholson K , Chan J , et al. Urate levels predict survival in amyotrophic lateral sclerosis: analysis of the expanded Pooled Resource Open-Access ALS clinical trials database. Muscle Nerve. 2018;57(3):430-434.</Citation></Reference><Reference><Citation>Paganoni S , Zhang M , Quiroz Z&#xe1;rate A , et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012;259(9):1923-1928.</Citation></Reference><Reference><Citation>K&#xfc;ffner R , Zach N , Norel R , et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nature Biotechnol. 2015;33(1):51-57.</Citation></Reference><Reference><Citation>Abraham A , Drory VE . Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014;261(6):1133-1138.</Citation></Reference><Reference><Citation>Zhang F , Zhang Q , Ke Y , et al. Serum uric acid levels in patients with amyotrophic lateral sclerosis: a meta-analysis. Sci Rep. 2018;8(1):1100.</Citation></Reference><Reference><Citation>Nagase M , Yamamoto Y , Miyazaki Y , Yoshino H . Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21(3):104-112.</Citation></Reference><Reference><Citation>Yamamoto Y . Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite. J Clin Biochem Nutr. 2017;60(1):49-54.</Citation></Reference><Reference><Citation>Nicholson K , Chan J , Macklin EA , et al. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2018;5(12):1522-1533.</Citation></Reference><Reference><Citation>Kawamata T , Akiyama H , Yamada T , McGeer PL . Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol. 1992;140(3):691-707.</Citation></Reference><Reference><Citation>McCauley ME , Baloh RH . Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137(5):715-730.</Citation></Reference><Reference><Citation>Graves M , Fiala M , Dinglasan LA , et al. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(4):213-219.</Citation></Reference><Reference><Citation>Henkel JS , Engelhardt JI , Sikl&#xf3;s L , et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol. 2004;55(2):221-235.</Citation></Reference><Reference><Citation>Engelhardt JI , Tajti J , Appel SH . Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol. 1993;50(1):30-36.</Citation></Reference><Reference><Citation>Murdock BJ , Zhou T , Kashlan SR , Little RJ , Goutman SA , Feldman EL . Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 2017;74(12):1446-1454.</Citation></Reference><Reference><Citation>Zhang R , Gascon R , Miller RG , et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol. 2005;159(1-2):215-224.</Citation></Reference><Reference><Citation>Prinz M , Priller J . The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci. 2017;20(2):136-144.</Citation></Reference><Reference><Citation>Khalid SI , Ampie L , Kelly R , Ladha SS , Dardis C . Immune modulation in the treatment of amyotrophic lateral sclerosis: a review of clinical trials. Front Neurol. 2017;8:486.</Citation></Reference><Reference><Citation>Cho Y , Crichlow GV , Vermeire JJ , et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA. 2010;107(25):11313-11318.</Citation></Reference><Reference><Citation>Fox RJ , Coffey CS , Conwit R , et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 2018;379(9):846-855.</Citation></Reference><Reference><Citation>Schwenkgrub J , Zaremba M , Joniec-Maciejak I , Cudna A , Mirowska-Guzel D , Kurkowska-Jastrzebska I . The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease. PLOS One. 2017;12(7):e0182019.</Citation></Reference><Reference><Citation>Suzumura A , Ito A , Yoshikawa M , Sawada M . Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 1999;837(1-2):203-212.</Citation></Reference><Reference><Citation>Kawanokuchi J , Mizuno T , Kato H , Mitsuma N , Suzumura A . Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology. 2004;46(5):734-742.</Citation></Reference><Reference><Citation>Mizuno T , Kurotani T , Komatsu Y , et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004;46(3):404-411.</Citation></Reference><Reference><Citation>Tominaga Y , Nakamura Y , Tsuji K , Shibata T , Kataoka K . Ibudilast protects against neuronal damage induced by glutamate in cultured hippocampal neurons. Clin Exp Pharmacol Physiol. 1996;23(6-7):519-523.</Citation></Reference><Reference><Citation>Matsuda K , Iwaki Y , Makhay M , Dojillo J , Yasui S . Interaction (nonuniformity) of ALS progression and the efficacy of MN-166 (ibudilast). 30th International Symposium on ALS/MND 2019.</Citation></Reference><Reference><Citation>Trias E , Ibarburu S , Barreto-N&#xfa;&#xf1;ez R , et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J Neuroinflammation. 2016;13(1):177.</Citation></Reference><Reference><Citation>Mora JS , Genge A , Chio A , et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;21:1-10.</Citation></Reference><Reference><Citation>Henkel JS , Beers DR , Wen S , et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64-79.</Citation></Reference><Reference><Citation>Beers DR , Zhao W , Wang J , et al. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2(5):e89530.</Citation></Reference><Reference><Citation>Kosmaczewska A . Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity. Int J Mol Sci. 2014;15(10):18574-18592.</Citation></Reference><Reference><Citation>Thonhoff JR , Beers DR , Zhao W , et al. Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e465.</Citation></Reference><Reference><Citation>Vucic S , Ryder J , Mekhael L , et al. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of Tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): study protocol clinical trial (SPIRIT Compliant). Medicine (Baltimore). 2020;99(6):e18904.</Citation></Reference><Reference><Citation>Cheng CW , Lin MJ , Shen CK . Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP. J Neurogenet. 2015;29(2-3):59-68.</Citation></Reference><Reference><Citation>Ryu HH , Jun MH , Min KJ , et al. Autophagy regulates amyotrophic lateral sclerosis-linked fused in sarcoma-positive stress granules in neurons. Neurobiol Aging. 2014;35(12):2822-2831.</Citation></Reference><Reference><Citation>Nalbandian A , Llewellyn KJ , Nguyen C , Yazdi PG , Kimonis VE . Rapamycin and chloroquine: the in vitro and in vivo effects of autophagy-modifying drugs show promising results in valosin containing protein multisystem proteinopathy. PLOS One. 2015;10(4):e0122888.</Citation></Reference><Reference><Citation>Wang IF , Guo BS , Liu YC , et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci USA. 2012;109(37):15024-15029.</Citation></Reference><Reference><Citation>Barmada SJ , Serio A , Arjun A , et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol. 2014;10(8):677-685.</Citation></Reference><Reference><Citation>Madill M , McDonagh K , Ma J , et al. Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms. Mol Brain. 2017;10(1):22.</Citation></Reference><Reference><Citation>Lattante S , de Calbiac H , Le Ber I , Brice A , Ciura S , Kabashi E . Sqstm1 knock-down causes a locomotor phenotype ameliorated by rapamycin in a zebrafish model of ALS/FTLD. Hum Mol Genet. 2015;24(6):1682-1690.</Citation></Reference><Reference><Citation>Mandrioli J , D'Amico R , Zucchi E , et al. Rapamycin treatment for amyotrophic lateral sclerosis: protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine (Baltimore). 2018;97(24):e11119.</Citation></Reference><Reference><Citation>Ben-Chetrit E , Bergmann S , Sood R . Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology (Oxford). 2006;45(3):274-282.</Citation></Reference><Reference><Citation>Gasparyan AY , Ayvazyan L , Yessirkepov M , Kitas GD . Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol. 2015;11(11):1781-1794.</Citation></Reference><Reference><Citation>Crippa V , D'Agostino VG , Cristofani R , et al. Transcriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases. Sci Rep. 2016;6:22827.</Citation></Reference><Reference><Citation>Mandrioli J , Crippa V , Cereda C , et al. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). BMJ Open. 2019;9(5):e028486.</Citation></Reference><Reference><Citation>Douville R , Liu J , Rothstein J , Nath A . Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol. 2011;69(1):141-151.</Citation></Reference><Reference><Citation>MacGowan DJ , Scelsa SN , Imperato TE , Liu KN , Baron P , Polsky B . A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS. Neurology. 2007;68(22):1944-1946.</Citation></Reference><Reference><Citation>McCormick AL , Brown RH Jr. , Cudkowicz ME , Al-Chalabi A , Garson JA . Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology. 2008;70(4):278-283.</Citation></Reference><Reference><Citation>Steele AJ , Al-Chalabi A , Ferrante K , Cudkowicz ME , Brown RH Jr. , Garson JA . Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology. 2005;64(3):454-458.</Citation></Reference><Reference><Citation>Andrews WD , Tuke PW , Al-Chalabi A , et al. Detection of reverse transcriptase activity in the serum of patients with motor neurone disease. J Med Virol. 2000;61(4):527-532.</Citation></Reference><Reference><Citation>Mayer J , Harz C , Sanchez L , et al. Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins. Mol Neurodegener. 2018;13(1):39.</Citation></Reference><Reference><Citation>Garson JA , Usher L , Al-Chalabi A , Huggett J , Day EF , McCormick AL . Quantitative analysis of human endogenous retrovirus-K transcripts in postmortem premotor cortex fails to confirm elevated expression of HERV-K RNA in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2019;7(1):45.</Citation></Reference><Reference><Citation>Shelkovnikova TA , An H , Skelt L , Tregoning JS , Humphreys IR , Buchman VL . Antiviral immune response as a trigger of FUS proteinopathy in amyotrophic lateral sclerosis. Cell Rep. 2019;29(13):4496-4508.</Citation></Reference><Reference><Citation>Alfahad T , Nath A . Retroviruses and amyotrophic lateral sclerosis. Antiviral Res. 2013;99(2):180-187.</Citation></Reference><Reference><Citation>Li W , Lee MH , Henderson L , et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. 2015;7(307):307ra153.</Citation></Reference><Reference><Citation>Bowen LN , Tyagi R , Li W , et al. HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy. Neurology. 2016;87(17):1756-1762.</Citation></Reference><Reference><Citation>Gold J , Rowe DB , Kiernan MC , et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7-8):595-604.</Citation></Reference><Reference><Citation>Doody RS , Gavrilova SI , Sano M , et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372(9634):207-215.</Citation></Reference><Reference><Citation>Cano-Cuenca N , Solis-Garcia del Pozo JE , Jordan J . Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis. J Alzheimers Dis. 2014;38(1):155-164.</Citation></Reference><Reference><Citation>Rosini M , Simoni E , Bartolini M , et al. The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon. ChemMedChem. 2013;8(8):1276-1281.</Citation></Reference><Reference><Citation>Skvortsova VI , Bachurin SO , Ustyugov AA , et al. Gamma-carbolines derivatives as promising agents for the development of pathogenic therapy for proteinopathy. Acta Naturae. 2018;10(4):59-62.</Citation></Reference><Reference><Citation>Strekalova T , Bahzenova N , Trofimov A , et al. Pro-neurogenic, memory-enhancing and anti-stress effects of DF302, a novel fluorine gamma-carboline derivative with multi-target mechanism of action. Mol Neurobiol. 2018;55(1):335-349.</Citation></Reference><Reference><Citation>Bachurin SO , Shelkovnikova TA , Ustyugov AA , et al. Dimebon slows progression of proteinopathy in gamma-synuclein transgenic mice. Neurotoxic Res. 2012;22(1):33-42.</Citation></Reference><Reference><Citation>Yamashita M , Nonaka T , Arai T , et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett. 2009;583(14):2419-2424.</Citation></Reference><Reference><Citation>Coughlan KS , Mitchem MR , Hogg MC , Prehn JH . &#x201c;Preconditioning&#x201d; with latrepirdine, an adenosine 5&#x2b9;-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging. 2015;36(2):1140-1150.</Citation></Reference><Reference><Citation>Ninkina N , Peters O , Millership S , Salem H , van der Putten H , Buchman VL . Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet. 2009;18(10):1779-1794.</Citation></Reference><Reference><Citation>Peters OM , Millership S , Shelkovnikova TA , et al. Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis. Neurobiol Dis. 2012;48(1):124-131.</Citation></Reference><Reference><Citation>Bronovitsky EV , Deikin AV , Ermolkevich TG , et al. Gamma-carboline inhibits neurodegenerative processes in a transgenic model of amyotrophic lateral sclerosis. Dokl Biochem Biophys. 2015;462:189-192.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>